UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Multiple sclerosis, 2008-11, Vol.14 (9), p.1157-1174

2008

Volltextzugriff (PDF)

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis, 2010-03, Vol.16 (3), p.342-350

2010

Volltextzugriff (PDF)

Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial

Neurology, 2002-11, Vol.59 (10), p.1496-1506

2002

Volltextzugriff (PDF)

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Multiple sclerosis, 2006-06, Vol.12 (3), p.309-320

2006

Volltextzugriff (PDF)

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Neurology, 1998-03, Vol.50 (3), p.701-708

1998

Volltextzugriff (PDF)

Influence of infection on exacerbations of multiple sclerosis

Annals of neurology, 1994, Vol.36 (S1), p.S25-S28

Panitch, Hillel S.

1994

Volltextzugriff (PDF)

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

Multiple sclerosis, 2008-06, Vol.14 (5), p.663-670

2008

Volltextzugriff (PDF)

Developmental changes in chest wall compliance in infancy and early childhood

Journal of applied physiology (1985), 1995-01, Vol.78 (1), p.179-184

1995

Volltextzugriff (PDF)

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

Neurology, 2008-03, Vol.70 (13 Pt 2), p.1134-1140

2008

Volltextzugriff (PDF)

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

Journal of neurology, 2008-10, Vol.255 (10), p.1473-1478

2008

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-08, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-04, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Neurology, 2002-10, Vol.59 (7), p.998-1005

CHAMPS Study Group

2002

Volltextzugriff (PDF)

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

The Lancet (British edition), 2005-08, Vol.366 (9485), p.579-582

2005

Volltextzugriff (PDF)

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial

Neurology, 1994-06, Vol.44 (6), p.1054-1054

1994

Volltextzugriff (PDF)

Bronchiolitis in infants

Current opinion in pediatrics, 2001-06, Vol.13 (3), p.256-260

Panitch, H B

2001

Volltextzugriff (PDF)

Interferons in multiple sclerosis : a review of the evidence

Drugs (New York, N.Y.), 1992-12, Vol.44 (6), p.946-962

PANITCH, H. S

1992

Volltextzugriff (PDF)

Intramedullary spinal cord abscess in a healthy woman

Neurology, 2007-04, Vol.68 (15), p.1230-1230

2007

Volltextzugriff (PDF)

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The New England journal of medicine, 2008-10, Vol.359 (17), p.1786-1801

2008

Volltextzugriff (PDF)

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis

Clinical therapeutics, 2007-09, Vol.29 (9), p.2031-2048

2007

Volltextzugriff (PDF)

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Multiple sclerosis, 2009-08, Vol.15 (8), p.959-964

2009

Volltextzugriff (PDF)

Respiratory Care of the patient with duchenne muscular dystrophy: ATS Consensus statement

American journal of respiratory and critical care medicine, 2004-08, Vol.170 (4), p.456-465

2004

Volltextzugriff (PDF)

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Annals of neurology, 2013-03, Vol.73 (3), p.327-340

2013

Volltextzugriff (PDF)

Exacerbations of multiple sclerosis in patients treated with gamma interferon

The Lancet (British edition), 1987-04, Vol.1 (8538), p.893-895

1987

Volltextzugriff (PDF)

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

Neurology, 2002-11, Vol.59 (10), p.1496

2002

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Aktive Filter

Publikationsformmagazinearticle

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Influence of infection on exacerbations of multiple sclerosis

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

Developmental changes in chest wall compliance in infancy and early childhood

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial

Bronchiolitis in infants

Interferons in multiple sclerosis : a review of the evidence

Intramedullary spinal cord abscess in a healthy woman

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Respiratory Care of the patient with duchenne muscular dystrophy: ATS Consensus statement

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Exacerbations of multiple sclerosis in patients treated with gamma interferon

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

Aktive Filter

Suchergebnisse filtern